Tagraxofusp Proves Effective for BPDCN, A Rare Blood Cancer


New findings from a clinical trial of the drug tagraxofusp confirm its efficacy against the rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Powered by WPeMatico